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Abstract
Objectives To evaluate the clinical effectiveness of group art therapy
for people with schizophrenia and to test whether any benefits exceed
those of an active control treatment.
Design Three arm, rater blinded, pragmatic, randomised controlled trial.
Setting Secondary care services across 15 sites in the United Kingdom.
Participants 417 people aged 18 or over, who had a diagnosis of
schizophrenia and provided written informed consent to take part in the
study.
Interventions Participants, stratified by site, were randomised to 12
months of weekly group art therapy plus standard care, 12 months of
weekly activity groups plus standard care, or standard care alone. Art
therapy and activity groups had up to eight members and lasted for 90
minutes. In art therapy, members were given access to a range of art
materials and encouraged to use these to express themselves freely.
Members of activity groups were offered various activities that did not
involve use of art or craft materials and were encouraged to collectively
select those they wanted to pursue.
Main outcomemeasures The primary outcomeswere global functioning,
measured using the global assessment of functioning scale, and mental
health symptoms, measured using the positive and negative syndrome
scale, 24 months after randomisation. Main secondary outcomes were
levels of group attendance, social functioning, and satisfaction with care
at 12 and 24 months.
Results 417 participants were assigned to either art therapy (n=140),
activity groups (n=140), or standard care alone (n=137). Primary
outcomes between the three study arms did not differ. The adjusted
mean difference between art therapy and standard care at 24 months
on the global assessment of functioning scale was −0.9 (95% confidence
interval −3.8 to 2.1), and on the positive and negative syndrome scale
was 0.7 (−3.1 to 4.6). Secondary outcomes did not differ between those
referred to art therapy or those referred to standard care at 12 or 24
months.
Conclusions Referring people with established schizophrenia to group
art therapy as delivered in this trial did not improve global functioning,
mental health, or other health related outcomes.
Trial registration Current Controlled Trials ISRCTN46150447.
Correspondence to: M J Crawford m.crawford@imperial.ac.uk
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Introduction
Schizophrenia is a severe mental disorder that affects as many
as 1 in 100 people at some point in their lives. In addition to
“positive” symptoms such as hallucinations and delusions, many
people also experience varying degrees of loss of energy and
motivation, impaired attention, and other so called negative
symptoms.1Although treatment with antipsychotic drugs reduces
the positive symptoms of schizophrenia and decreases the
likelihood of relapse, it has little impact on negative
symptoms.2 3 Psychological and social interventions are widely
used in combination with drugs in an effort to further improve
the health and social outcomes of people with schizophrenia,
and several interventions have been shown to be effective.4
The possibility that involvement in creative activities can
improve health has often been discussed but rarely examined.5
It has been argued that for people with severe mental disorders
such as schizophrenia, art therapy has advantages over other
treatments because the use of art materials can help people to
understand themselves better while containing powerful feelings
that might otherwise overwhelm them.6 Few attempts have been
made to examine the effectiveness of group art therapy as an
adjunctive treatment for people with schizophrenia,7 but the
results of a pilot trial suggested that it may help bring about
clinically important reductions in negative symptoms of
schizophrenia.8 Findings of this study, together with those of
trials of other creative therapies, have resulted in the inclusion
of arts therapies in national treatment guidelines, which
recommend that clinicians consider referring all people with
schizophrenia for arts therapies, particularly for the alleviation
of negative symptoms of the disorder.3
We examined the impact of adding group art therapy to the
treatment of people with schizophrenia compared with both
active control treatment and standard care alone on global
functioning and symptoms of schizophrenia.
Methods
The MATISSE (Multicenter study of Art Therapy In
Schizophrenia: Systematic Evaluation) studywas a rater blinded,
parallel group, randomised controlled trial of either group art
therapy plus standard care, activity groups plus standard care,
or standard care alone.9 We carried out a parallel economic
evaluation (reported elsewhere) and a process evaluation, which
examined the organisation and delivery of treatment in the study
and the relation between treatment process and treatment
outcomes.
Participants
Study participants were recruited from community basedmental
health and social care services in four centres in England and
Northern Ireland. We also considered inpatients, but eligible
participants were not randomised until after discharge from
inpatient care. Participants were aged 18 years or over and had
a clinical diagnosis of schizophrenia, confirmed by an
examination of case notes using operationalised criteria.10 To
take part in the study, potential participants had to be willing
to take part in group therapy and to provide written informed
consent. We excluded those with severe cognitive impairment,
those who were unable to speak sufficient English to complete
the baseline assessment, and those already receiving art or
another creative therapy. Health and social care professionals
working on inpatient units or in community teams, day centres,
and rehabilitation and residential units identified potential
participants. Researchers and clinical studies officers of the UK
Mental Health Research Network met those who had given
verbal consent to be approached about the study, assessed
eligibility, providedwritten and verbal information, and obtained
written informed consent.
Randomisation and masking
Following completion of baseline assessments, participants
were randomised through an independent and remote telephone
randomisation service provided by the Aberdeen Clinical Trials
Unit. We used permuted blocks, stratified by site. Block size
was randomly assigned between three and six. Participants and
clinical staff were aware of the trial arm to which the study
participants were allocated but all interviews were done by
researchers blinded to allocation status. Researchers were asked
to guess what arm participants had been randomised to after the
final follow-up interview had been completed.
Interventions
Those randomised to group art therapy were offered weekly
sessions of 90 minutes’ duration for an average of 12 months.
Art therapy was carried out in keeping with recommendations
of the British Association of Art Therapists11 and aimed to
enhance self expression, improve emotional health, and help
people develop better interpersonal functioning. Patients were
given access to a range of art materials and encouraged to use
these to express themselves freely. Art therapists generally
adopted a supportive approach, offering empathy and
encouragement. They rarely provided psychotherapeutic
interpretations of interpersonal process or images. They did,
however, frequently discuss these processes in supervision.
Within this framework, therapists employed specific therapeutic
interventions considered appropriate to individual needs and
circumstances. This approach is in keeping with
recommendations for the pragmatic evaluation of complex
interventions in which individual therapists are encouraged to
apply treatment principles flexibly to fit with the needs of
participants.12
Activity groups also took place on a weekly basis and were
made available to participants for an average of 12 months.
Facilitators of these groups encouraged participants to agree
activities collectively; these included playing board games,
watching and discussing DVDs, and visiting local cafes. The
use of art materials was prohibited. Group facilitators were
asked to refrain from exploring the thoughts and feelings of
study participants or offering psychotherapeutic interventions.
All art therapy and activity groups were cofacilitated by a
member of staff or volunteer who received training in the trial
and intervention. During the treatment phase of the trial, art
therapists and activity group facilitators received monthly group
supervision from a senior practitioner with relevant expertise.
Recordings of each supervision session were reviewed by a
senior member of the study team who provided feedback to
supervisors about adherence to agreed guidelines for the delivery
of respective interventions. Standard care involved follow-up
from secondary care mental health services, care coordination,
pharmacotherapy, and the option of referral to other services as
clinically indicated, except other creative therapies, which
participants agreed not to undertake until completion of
follow-up.
Outcome measures
The primary outcomes for the study were global functioning
(measured using the global assessment of functioning scale)13
and symptoms of schizophrenia (measured using the positive
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and negative syndrome scale) assessed at 24months.14 Secondary
outcomes were global functioning and mental health symptoms
measured at 12 months as well as levels of group attendance,
social functioning (measured using the social function
questionnaire),15 adherence with prescribed drugs (measured
using the Morisky scale),16 satisfaction with care (measured
using the client satisfaction questionnaire),17 mental wellbeing
(measured using the general wellbeing scale),18 and health related
quality of life (measured using the five item EQ-5D)19 assessed
at 12 and 24 months after randomisation.20
Statistical analysis
The sample size was based on detecting a minimal clinically
significant difference of 6 (SD 10) points on the global
assessment of functioning scale at 24 months, between those
randomised to art therapy and those randomised to active control
or standard care alone. Taking into account an inflation factor
for therapist clustering of 2.22 (based on eight participants or
therapists and an intraclass correlation coefficient of 0.175) and
a 20% loss to follow-up, we aimed to recruit 376 participants.
All primary statistical analyses were done using the intention
to treat principle. We imputed missing baseline data using
regression or mean imputation. Follow-up data were not
imputed. Differences in mean score between those randomised
to each of the three trial arms were examined using analysis of
covariance adjusting for baseline value of the outcome, site,
sex, and age. All secondary outcomes (positive and negative
syndrome scale and global assessment of functioning score at
12 months, and positive and negative syndrome scale; negative,
positive, and general symptoms subscales; social function;
wellbeing; drugs; and satisfaction with services at 12 and 24
months) were analysed in a similar way. We report any
significant findings. To take into account the clustered structure
of the data we fitted different mixed effects models as sensitivity
analyses, including a two level heteroscedastic model allowing
the within site variance to differ across arms, and a three level
model, with study centre as level 3 and site as level 2.21
In another secondary analysis we examined the impact of the
uptake of the interventions on our primary outcomes using two
stage least squares estimates.22 This analysis is based on
instrumental variable methods and avoids the selection bias of
per protocol or as treated analysis. The approach assumes that
the effect of allocation to treatment has no effect on the outcome
if the patient does not receive the treatment. As there are no
data to suggest that there is a minimum number of sessions of
art therapy that someone needs to attend to derive benefit from
this intervention, we used this approach to estimate the benefit
per session, assuming it is proportional to the number of sessions
attended, when adjusted for site, sex, and age. All P values were
two sided and considered significant when less than 0.05.
Results
In total, 649 people were assessed for the study over a 19month
period between February 2007 and August 2008. Of these, 417
(64%) were randomised, 361 (87%) were followed up at 12
months, and 355 (85%) were followed up at 24 months. The
figure⇓ presents the reasons for non-participation and attrition.
Table 1⇓ shows the baseline characteristics of the participants.
Study participants had a mean age of 41 and a mean duration
of illness of 17 years. All but 15 (4%) were being prescribed
antipsychotic drugs, and 134 (32%) had had a period of inpatient
psychiatric treatment in the 12 months before randomisation.
The attrition rate was similar across arms, and reasons for
attrition did not differ (death, withdrawal, lost to follow-up).
Of the seven deaths, four were from suicide or probable suicide.
Three additional serious adverse events were reported, one a
near fatal episode of deliberate self harm and two involving
harm to others. None seemed to be related to the interventions
being examined in the study.
Participants who completed follow-up had baseline
characteristics similar to those who did not, but attrition rates
varied by study centre. When researchers attempted to guess
allocation status after the final follow-up interview, almost half
of the guesses were correct (n=119, 48%).
Those allocated to art therapy attended between 0 and 51 groups,
and those allocated to control groups attended between 0 and
45 groups. Eighty six (61%) of those randomised to art therapy
and 73 (52%) randomised to activity control groups attended
at least one group. Among those who attended one or more
groups, median levels of attendance were higher among those
randomised to group art therapy (11 for art therapy versus five
for activity groups, P=0.04). The median delay between
randomisation and someone attending his or her first group was
61 days for both art therapy and activity groups. The content of
audio recordings showed that supervision sessions of both art
therapy and activity groups were delivered in a consistent
manner across study centres.
Table 2⇓ presents the baseline and follow-up outcome scores
by trial arm. During the two year follow-up period, the number
of total symptoms of schizophrenia decreased. No differences
in primary outcomes were found between trial arms. The
adjusted mean difference between those randomised to art
therapy and those randomised to standard care alone on the
global assessment of functioning scale was −0.9 (95%
confidence interval −3.8 to 2.1, P=0.57) and on the positive and
negative syndrome scale was 0.7 (−3.1 to 4.6, P=0.71). The
adjusted mean difference between those randomised to art
therapy and those randomised to activity groups on the global
assessment of functioning scale was −1.1 (−4.0 to 1.8, P=0.47)
and on the positive and negative syndrome scale was 3.1 (−0.7
to 6.9, P=0.11). Global assessment of functioning scores at 24
months showed little clustering across study sites (intraclass
correlation coefficient 0.06), but variance between sites in scores
on the positive and negative syndrome scale was important
(intraclass correlation coefficient 0.47). None of the mixed
models that were fitted to take into account the clustered
structure of the data showed significant differences in the
primary outcome between groups.
Wellbeing, satisfaction with care, or other secondary outcomes
at 12 and 24 months did not differ significantly, except that
those referred to an activity group had fewer positive symptoms
of schizophrenia at 12 and 24 months compared with those
randomised to group art therapy (adjusted mean difference 1.4,
95% confidence interval 0.1 to 2.6, P=0.03).
Analysis of instrumental variables indicated that attendance at
art therapy groups was not associated with improvements in
global functioning or in symptoms of schizophrenia (table 3⇓).
Discussion
In this randomised trial the mental health and global functioning
of people with schizophrenia was not improved by offering a
place in a weekly art therapy group in addition to their standard
care. Those randomised to weekly group art therapy had similar
levels of global functioning and mental health as those
randomised to an activity control group over a two year period,
except that the activity control group had a greater reduction in
positive symptoms of schizophrenia at 24 months. People
offered a place in an art therapy group were more likely to attend
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sessions than those offered a place in an activity group, but
levels of attendance at both types of group were low.
Strengths and weaknesses of the study
The main strengths of the study are that it was adequately
powered, used a rigorous approach to minimising bias, and used
broad inclusion criteria to assess whether the intervention could
help most people with schizophrenia. Data from a national
survey of art therapists working throughout England and carried
out in parallel with this trial suggested that the approach used
to deliver art therapy in the study is the same as that used more
widely across the country.23The studywas not, however, without
its limitations, chief among these being the level of engagement
with the intervention. We deliberately set out to test the
effectiveness of group art therapy among most people with
schizophrenia who expressed a willingness to use this form of
treatment. Almost 40% of participants randomised to group art
therapy did not attend any sessions. Among those who did, few
attended regularly. Possible explanations for the low level of
attendance are that the interventions may not have been
acceptable to participants or that participants lacked the
motivation and organisational skills to attend.24 However, the
average effect of attendance at art therapy among the compliant
population was estimated in a two stage least squares estimation,
which suggested that even in those willing to participate in art
therapy, attendance was not related to study outcomes.
Many groups had only one or two regular attendees, with an
average of two or three people attending art therapy groups.
Although this meant that therapists may have been able to pay
greater attention to each participant than would have been
possible in a larger group, opportunities for group members to
interact with each other were more limited.25
We did not collect outcome data during the intervention phase
of the study, potentially precluding observation of short term
benefits. However, the absence of statistically or clinically
significant differences in outcomes between participants in the
three intervention arms at 12 months suggests that even if short
term benefits did occur, these dissipated within a year. Previous
accounts of the potential benefits of group art therapy suggest
that it may help people in ways that are difficult to quantify.25
We do not knowwhether art therapy resulted in other outcomes
that are valued by service users but were not measured in this
trial. Nevertheless, our study did not corroborate the findings
of other small smaller scale trials of creative therapies that have
shown improvements in symptoms of schizophrenia.26
Comparison with other studies
Levels of attendance at group art therapy were also low in the
two previous community based randomised trials of group art
therapy. In the first ever clinical trial of art therapy, the
researchers studied 47 people with chronic mental illness of
whom half had a diagnosis of schizophrenia.27 Detailed
information about levels of attendance were not provided but
the authors state that among 19 people who were followed up,
eight (42%) attended fewer than three sessions of art therapy.
The authors compared outcomes between patients who
completed 10 groups with those who did not and found that the
completers had higher levels of self esteem.
In a subsequent trial, the researchers examined the effects of
adding up to 12 sessions of weekly group art therapy to the
standard care of people with schizophrenia.8 Among those
offered a place in an art therapy group, mean attendance was
3.5 sessions, and 37% attended no sessions at all. Fewer than
half of all participants were followed up at six months, but
among those who were followed up a statistically significant
reduction in negative symptoms was found. It is unclear whether
the researchers who carried out follow-up assessments in these
trials were masked to the allocation status of participants.
Conclusions and future research
These findings challenge current national treatment guidelines
that clinicians should consider referring all people with
schizophrenia for arts therapies.3 Although we cannot rule out
the possibility that group art therapy benefits people with
schizophrenia who are motivated to use this treatment, our
findings suggest that it does not lead to improved patient
outcomes when offered to most people with this disorder.
Levels of attendance at art therapy may be higher when people
are receiving inpatient treatment,28 and the impact of art therapy
delivered in this setting should be studied.
Results of randomised trials of other creative therapies for
people with schizophrenia, such as music therapy and body
movement therapy, are more promising.29 30 These interventions
combine creativity with other approaches specifically aimed at
providing an enjoyable experience, stimulating physical
movement, and increasing interactions with others. Although
it has been argued that involvement in creative activities is
inherently good for mental health, it may be that for people with
severe mental illnesses such as schizophrenia it is only when
such activities are used in combination with other interventions
that benefits are seen.
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What is already known on this topic
Although drugs can reduce the symptoms of schizophrenia, many people still experience poor mental health and social functioning
Group art therapy has been used as adjunctive treatment for people with schizophrenia, but few studies have examined its clinical effects
What this study adds
Group art therapy, as delivered in this trial, did not improve global functioning or health outcomes of people with schizophrenia
Levels of attendance at both art therapy and activity groups were low
Although group art therapy may benefit a few highly motivated people, evidence of improved patient outcomes for most people with
schizophrenia was lacking
Arts Therapies) that aims to promote research and development of arts
therapies in health and social care.
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Tables
Table 1| Personal characteristics of participants at baseline. Values are numbers (percentages) unless stated otherwise
Total (n=417)Art therapy (n=140)Activity group (n=140)Standard care (n=137)Variable
41 (12)41 (11)42 (12)40 (12)Mean (SD) age (years)
279 (67)90 (64)90 (64)99 (72)Men
138 (33)50 (36)50 (36)38 (28)Women
Marital status:
31 (7)11 (8)12 (9)8 (6)Married or cohabiting
47 (11)17 (12)21 (15)9 (7)Divorced or separated
5 (1)1 (1)1 (1)3 (2)Widowed
334 (80)111 (79)106 (76)117 (85)Single
Education*:
45 (11)12 (9)15 (11)18 (14)Degree
177 (44)59 (43)64 (46)54 (42)Other
53 (13)18 (13)13 (9)22 (17)Vocational training
129 (32)48 (35)46 (33)35 (27)None
*Data on 404 participants.
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Table 2| Main and secondary outcomes at baseline and 12 and 24 months. Values are means (SDs)
Group art therapyActivity groupsStandard care
Outcome measure*
24 months
(n=117)
12 months
(n=119)
Baseline
(n=140)
24 months
(n=121)
12 months
(n=121)
Baseline
(n=140)
24 months
(n=117)
12 months
(n=121)
Baseline
(n=137)
Primary outcomes:
45.6 (13.1)44.9 (14.6)44.8 (13.1)46.4 (13.6)45.5 (14.1)45.0 (12.7)46.8 (12.8)45.7 (14.4)44.9 (12.6)Global assessment
of functioning (n=355)
69.2 (21.8)72.7 (27.3)74.3 (23.7)66.9 (23.3)69.6 (23.2)75.3 (22.0)68.1 (20.7)71.2 (24.6)72.6 (21.5)Positive and negative
syndrome scale total
score (n=348)
Secondary outcomes:
16.8 (6.5)17.3 (7.6)18.0 (6.9)15.6 (6.4)16.1 (5.9)18.2 (6.8)16.1 (5.5)16.7 (6.3)17.3 (5.6)Positive symptoms
score (n=348)
16.9 (7.1)18.4 (8.0)18.7 (7.1)16.4 (6.8)17.3 (7.2)18.7 (7.0)17.2 (7.3)18.2 (7.7)18.5 (7.5)Negative symptoms
score (n=348)
35.3 (11.4)37.0 (14.0)37.6 (12.5)34.9 (12.4)35.9 (12.7)37.6 (12.5)34.9 (11.3)36.3 (13.0)36.8 (11.3)General symptoms
score (n=348)
8.2 (4.8)8.3 (5.0)8.6 (4.2)8.0 (4.5)8.1 (4.6)9.0 (4.8)8.1 (4.8)8.5 (4.9)8.1 (4.7)Social functioning
(n=348)
65.1 (18.6)59.6 (20.8)58.3 (21.1)66.1 (18.4)63.6 (23.2)59.1 (19.5)68.1 (18.8)64.1 (23.7)64.5 (20.6)Wellbeing (n=348)
23.1 (5.9)23.6 (6.5)24.8 (5.7)24.9 (5.0)25.0 (5.2)23.8 (6.2)24.2 (5.3)24.3 (6.4)24.9 (5.7)Satisfaction with care
(n=329)
0.6 (0.9)0.7 (1.0)1.0 (1.2)0.5 (0.9)0.6 (0.9)1.2 (1.3)0.6 (0.9)0.7 (1.1)1.2 (1.3)Morisky score†
(n=333)
*Bracketed data are numbers completing each outcome measure at 24 months.
†Adherence with prescribed drugs.
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Table 3| Instrumental variables analysis at 24 month follow-up, adjusted for site, sex, and age
P valueCoefficient (95% CI)Variables
Global assessment of functioning (n=355):
0.55−0.08 (−0.35 to 0.19)Group art therapy versus standard care
0.910.02 (−0.38 to 0.43)Group art therapy versus activity group
Positive and negative syndrome scale (n=340):
0.690.07 (−0.28 to 0.42)Group art therapy versus standard care
0.24−0.31 (−0.84 to 0.21)Group art therapy versus activity group
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Figure
Flow of participants through study
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e846 doi: 10.1136/bmj.e846 (Published 28 February 2012) Page 9 of 9
RESEARCH
